Mr. Lanfear, InteKrin’s founder, became Chairman of the Board in 2010. Under Mr. Lanfear’s five year leadership as President and CEO, the company was taken from inception through a successful End-Of-Phase-2 meeting with the FDA and into Phase 3 with a major therapeutic area lead product of high market potential.

Denny is a thirteen year veteran of Amgen, Inc. where he was a Corporate Officer and Vice-President with broad operational, product development and marketing responsibility. His tenure began in 1986 as founder of the Process Development Department. Under his ten-year leadership this group became the preeminent PD organization in BioPharma and a key strategic advantage for the company, as it remains today. As Vice President Process Development and Operations Systems, he directed the business process integration of over twenty-five hundred Operations and Quality staff world-wide.

While at Amgen he also had senior leadership roles in several product development programs including those for growth factors, somatotrophins and neurotrophins, directing efforts from preclinical to Phase III. He reviewed and wrote sections of more that 20 INDs and several BLAs. He managed several corporate partner relationships including that with SKB from 1986 to 1990. He also managed and had direct budgetary responsibility for the $135M development partnership with Regeneron Pharmaceuticals from 1991 to 1999. In 1997 he was named Vice President, Market Development, where he defined long term competitive and reimbursement strategies for Epogen®, a multibillion dollar drug.

Prior to joining Amgen, Denny held positions of increasing responsibility at Baxter International. Denny was also the founder and former CEO of Saronyx, Inc., a drug development software services company. He is also an active life science investor through his firm Lanfear Capital Advisers, which invests in pharmaceutical and medical device companies. He is an investor and former Director of Anthera Pharmaceuticals. He is a Director of Insmed Therapeutics. Lanfear Capital is also Limited Partner in select venture funds.

Denny earned degrees in Biochemistry and Chemical Engineering from Michigan State University and earned his MBA from the Anderson School at UCLA.

Mr. Brand brings more than 30 years of global pharmaceutical experience in product development, acquisitions, marketing and operational management with GlaxoSmithKline, its predecessor companies, and most recently as President and CEO of Cardiokine.

Mr. Brand joined GSK International from the Canadian operation in 1983 in the post of Vice President, Cardiovascular/Gastrointestinal Marketing. Over the next 7 years, he held VP positions in marketing, business development, and regional operations in Asia, Europe and Latin America.

In 1990, Mr. Brand joined the GSK US organization as Business Unit Head for Gastrointestinal and Central Nervous System Products, where he led the launch activities for Paxil and Kytril. In 1994, as Vice President of New Product Planning, he was responsible for the pre-launch commercial development plans for Coreg, Hycamptin, Requip and numerous in-licensing, co-promotion, co-development partnerships. From 1997 through 2003, Mr Brand headed up the anti-infective, metabolic and cardiovascular business units that launched Requip, Avandia and Avandia extensions, and development of Augmentin ES/XR.

From 2004 to September 2007, Mr. Brand served as President and CEO of Cardiokine, a specialty pharmaceutical company developing lixivaptan. Over this period, Mr. Brand built a first class management and development team, successfully closed a $50 million Series B financing and completed a global lixivaptan co-development, co-marketing agreement with Biogen Idec.

Mr. Brand holds a Bachelor of Commerce degree from Concordia University in Montreal, Canada.

Martin Freed, M.D., spent nearly 14 years at GlaxoSmithKline and its predecessor, SmithKline Beecham Pharmaceuticals. He was Vice President, Clinical in the Metabolism Therapeutic Area, where he led clinical development for diabetes and obesity drugs. For over 12 years, Dr. Freed played a substantial role in the development of the Avandia-related franchise. He personally managed the clinical pharmacology development and subsequently led a team responsible for clinical development, life cycle management, and medical affairs of the GSK diabetes franchise, including Avandia, Avandamet and Avandaryl. From 2005 to 2007, Dr. Freed served as Chief Medical Officer at Vitae Pharmaceuticals, Inc.. Since June 2007, Dr. Freed has served as Chief Medical Officer at Adnexus Therapeutics, which discovers and develops a novel, proprietary class of targeted biologics called Adnectins™.

Dr. Freed has been involved in the clinical development of drugs across a broad range of therapeutic areas including metabolic diseases, cardiovascular disease and diseases of inflammation with experiences ranging from Phase I through Phase IV. He has authored over 100 publications or presentations. A Fellow of the American College of Physicians, Dr. Freed received his Doctor of Medicine from Pennsylvania State University’s College of Medicine and graduated magna cum laude with a Bachelor of Arts with Distinction in Biology from the University of Delaware. Dr. Freed is Board Certified in Internal Medicine, Nephrology and Clinical Pharmacology. He performed his internal medicine residency and nephrology fellowship at Temple University Hospital and Yale New Haven Hospital, respectively.

Jim Healy, M.D., Ph.D., General Partner, joined Sofinnova in the spring of 2000. In the words of one entrepreneur, Jim has an "unparalleled work ethic." Prior to joining Sofinnova, he had experience with both pharmaceutical products and research platforms. In the pharmaceutical industry he held a manufacturing position at Bayer Pharmaceuticals (Miles) and helped guide the discovery group at ISTA Pharmaceuticals prior to its initial public offering. He also has experience with research tools and platforms through his involvement at the Human Genome Center at Lawrence Berkeley Labs.

Jim has authored or co-authored numerous research articles and reviews, including three papers published in Nature. He began his private equity career at Sanderling. Jim earned B.A.s in Molecular Biology and Scandinavian Studies from the University of California at Berkeley, where he graduated with Distinction in General Scholarship, Honors, and received the Departmental Citation. Jim received his M.D. from Stanford School of Medicine through the Medical Scientist Training Program, and earned his Ph.D. in Immunology from Stanford University, where he was a Beckman Scholar and received a bursary award from the Novartis Foundation.

Linda S. Higgins, Ph.D., is the President & CEO at InteKrin Therapeutics, Inc. Dr. Higgins joined InteKrin in 2007 and has over 18 years of experience in the pharmaceutical industry. Previously she was with Scios, Inc. where she was most recently Head of Research holding responsibility for drug discovery, preclinical development, and translational medicine. She has led multiple teams for programs in discovery through early clinical development focused on CNS, inflammatory, oncology, cardiovascular, hematology and fibrotic disorders which were advanced internally as well as in partnership with major pharmaceutical companies. During her tenure at Scios, it grew from a discovery organization, to a fully integrated biopharmaceutical company marketing a product discovered in house, to an operating company owned by Johnson & Johnson. Dr. Higgins has authored over 50 original peer reviewed scientific papers and invited reviews, and is inventor on over a dozen patents. She earned an AB in Behavioral Physiology with High Honors and Distinction from Kenyon College, Gambier Ohio; a PhD in Neurosciences from the University of California, San Diego School of Medicine; and postdoctoral training in Molecular Genetics at the Howard Hughes Medical Institute at the University of California, Berkeley.

David has been involved as a research scientist, manager and leader of drug discovery programs, and advisor and investor in life sciences companies since 1985. Trained as a molecular biologist, he was at Genentech (NYSE:DNA) for 16 years, and was Director of Cardiovascular Research there from 1993 to 1999. At Genentech, David led drug discovery activities in biologics and small molecule therapeutics. He was responsible for drug discovery efforts that resulted in eight drug candidates taken into clinical development, including the successful cancer therapy Avastin™. David was a member of the therapeutic area team responsible for cardiovascular strategic planning and product portfolio management, and worked extensively with Business Development on in-licensing of early and late-stage therapeutics, and technology access. David holds BS and PhD degrees in biochemistry from the University of Toronto, Canada. He has authored over 60 peer-reviewed scientific publications and is an inventor on 7 issued or pending US patents. He is a member of the Advisory Board of the Institute of Molecular Medicine at the University of California, San Diego. He joined Skyline in 2002 as a Kauffman Fellow, and became a partner in 2003. He is an ardent SCUBA diver, underwater photographer, and (perhaps because he believes the financial warning that past results do not necessarily predict future performance) roots for either the Red Sox or Yankees depending on who's winning.

Lowell E. Sears has been Chairman and Chief Executive Officer of Sears Capital Management, Inc., a life sciences venture capital and portfolio management company, since 1994. Prior to founding Sears Capital Management, Mr. Sears was Chief Financial Officer of Amgen, Inc. from 1988 to 1994 as well its Senior Vice President responsible for the Asia-Pacific region.

Mr. Sears served as Amgen's Treasurer and Director of Planning from 1986 to 1988. From 1976 to 1986, Mr. Sears held senior financial and planning positions with Atlantic Richfield Company, an integrated oil company, including several years as Chief Financial Officer of its Ventures Division. Mr. Sears received his B.A. degree in economics from Claremont McKenna College and his M.B.A. from Stanford University.